Multiple Sclerosis and Relapsing Disease Forms
Tg Therapeutics Inc. focuses on relapsing multiple sclerosis and related relapsing disease presentations, with clinical activity centered on long-term safety, efficacy, and radiological outcomes in people living with active disease.
- Relapsing forms of multiple sclerosis
- Relapsing multiple sclerosis
- Radiological disease activity
The sponsor’s work in this area includes adult and pediatric populations, reflecting interest across different stages of multiple sclerosis care.
Anti-CD20 Immunotherapy
Clinical research also addresses anti-CD20 therapy in autoimmune disease, with attention to treatment response in participants who have had a suboptimal experience with prior therapy and to maintaining disease control over time.
- Anti-CD20 therapy
- Autoimmune diseases
- Treatment response
This therapeutic area links immune modulation with neurologic disease management, especially in relapsing conditions.
Pediatric Neurology
The sponsor funds studies in children and adolescents with relapsing forms of multiple sclerosis, highlighting interest in age-specific treatment performance, safety, and clinical effectiveness in younger patients.
- Pediatric multiple sclerosis
- Adolescent patients
- Long-term safety
These studies extend the sponsor’s neurologic research into earlier disease onset and pediatric treatment needs.
Pharmacokinetics and Pharmacodynamics
A substantial part of the sponsor’s portfolio examines pharmacokinetics and pharmacodynamics of ublituximab, including comparisons of intravenous and subcutaneous administration and evaluation of relative bioavailability.
- Ublituximab
- Intravenous and subcutaneous administration
- Relative bioavailability
Research in this domain includes both delivery route exploration and device-based administration approaches.
Biologic Delivery and Administration Devices
Tg Therapeutics Inc. is also involved in studies of subcutaneous injection methods, including different injection sites and use of an autoinjector device versus syringe, with a focus on treatment practicality in multiple sclerosis.
- Subcutaneous injection
- Autoinjector device
- Injection site evaluation
These areas reflect interest in how biologic therapies are administered in routine neurologic care.
